HEALTH

Oruka Therapeutics' stock rose over 14% due to positive investor sentiment on its clinical pipeline, highlighting the biotechnology sector's potential for substantial returns.

Apogee Therapeutics' stock surged 46% due to positive investor reactions to its clinical advancements, highlighting the biotechnology sector's potential for dramatic market movements.

Definium Therapeutics' stock surged over 54% due to heightened investor interest in its research pipeline and strategic initiatives, reflecting optimism in the biotechnology sector's potential for innovation and growth.

Butterfly Network's stock surged 56% after announcing a partnership with AI startup Midjourney, highlighting a promising future in medical imaging technology despite ongoing profitability challenges.

4DMedical Ltd's stock surged 17.62% as the company expands its respiratory imaging technology across the U.S. and Europe, driven by regulatory clearances and commercial contracts.

Biohaven Ltd. shares rose over 12% due to positive developments in its clinical pipeline, focusing on immunology, neuroscience, and obesity treatments, with analysts projecting significant upside potential.

uniQure's stock surged over 75% after the FDA approved a regulatory path for its AMT-130 gene therapy targeting Huntington's disease, marking a significant milestone for the biotech company.

GSK acquires Nuvalent for $10.6 billion, enhancing its oncology portfolio with promising lung cancer therapies. The deal offers a 40% premium, reflecting Nuvalent's strong clinical pipeline.

Tango Therapeutics' shares rose over 50% following promising Phase 1/2 trial results for a new pancreatic cancer treatment, showing a 92% response rate and potential for significant advancements in oncology.

Tango Therapeutics' stock surged over 32% due to positive developments in its precision oncology pipeline, highlighting investor enthusiasm for its synthetic lethality platform targeting genetically defined cancers.

Moderna faces a pivotal year in 2026, transitioning from pandemic-driven revenues to diversified growth in vaccines and oncology, while managing financial challenges and clinical risks.

CooperCompanies' shares rose over 7% after reporting record second-quarter revenue and earnings, marking the tenth consecutive quarter of exceeding expectations, driven by strong demand for contact lenses.

Oscar Health's shares rose 12.68% following a strong earnings report, highlighting improved profitability and membership growth. The company's tech-driven model and optimistic 2026 outlook have boosted investor confidence.

MiniMed Group Inc. shares rose over 11% following strong financial results and a positive outlook, driven by demand for its automated insulin delivery systems and strategic collaborations.

Relay Therapeutics' shares rose over 20% following positive updates on its precision oncology pipeline at ASCO 2026, highlighting the potential of its lead candidate, zovegalisib, in treating breast cancer.

Legend Biotech's shares rose 20% following positive clinical data on its LB2102 CAR-T therapy for solid tumors, presented at ASCO. The results indicate potential expansion beyond multiple myeloma.

Edgewise Therapeutics' stock rose 15.38% due to promising clinical progress in treating rare muscle disorders, boosting investor confidence and market capitalisation amid a positive biotechnology sector environment.

Erasca Inc. is gaining attention in the biotechnology sector with its focus on RAS/MAPK pathway-driven cancers. Analysts recommend buying amid promising clinical data, despite inherent risks in the field.

Agilent Technologies' shares rose 14% after exceeding Q2 expectations and raising its full-year guidance, driven by strong demand in AI-related applications and growth in life sciences and diagnostics.

Erasca Inc. shares rose nearly 9% as investors responded positively to promising clinical data for its cancer therapy, ERAS-0015, and strategic collaborations aimed at advancing its oncology pipeline.

Fisher & Paykel Healthcare's shares rose over 9% following strong full-year results, driven by global demand for respiratory care products and strategic growth initiatives.

Guardant Health's shares rose over 10% following strong Q1 2026 results and increased revenue guidance, driven by significant growth in oncology and screening revenues.

Roivant Sciences' shares rose significantly after Immunovant's trial of IMVT-1402 showed promising results in treating difficult rheumatoid arthritis, highlighting the company's strong pipeline and financial position.

Immunovant's shares rose significantly after reporting positive trial data for IMVT-1402 in rheumatoid arthritis, despite a wider net loss. The promising results highlight potential for deeper IgG reduction.

Daraxonrasib, a new drug targeting the KRAS mutation in pancreatic cancer, shows potential to double survival times, generating high demand and cautious optimism among patients and oncologists.

SYDNEY — Australia's healthcare sector enters 2026 amid robust growth in digital and wellness markets, significant public hospital funding boosts and private health insurance premium hikes that have consumers rethinking coverage, as the system grapples with an aging population, chronic disease pressures and calls for deeper preventive care reforms.

ImmunityBio Inc.'s stock has skyrocketed in early 2026, surging more than 500% year-to-date and hitting new 52-week highs above $11 as explosive sales growth for its flagship immunotherapy ANKTIVA, coupled with rapid international regulatory approvals and partnerships, fuels investor enthusiasm for the cancer-focused biotech.

Hims & Hers Health Inc. (NYSE: HIMS) shares tumbled sharply in trading on Tuesday, February 24, 2026, falling as much as 9%

Dr. Fauci has again praised Australia for its successful handling of the COVID-19 pandemic and containing the spread of the virus.